Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of lung cancer known as non-small-cell lung cancer (NSCLC) that has specific changes in the EGFR gene. These changes, called EGFR mutations, can affect how cancer grows. The study is looking at two medications, dacomitinib (also known as PF-00299804) and osimertinib (also known as AZD9291), to find out the best way to use them in treating this type of lung cancer. Both medications are taken as film-coated tablets.

The purpose of the study is to determine the most effective order of using these medications in patients with advanced or metastatic NSCLC that has EGFR mutations. The study will include patients who have not been treated with these types of medications before. It will also include patients who have brain metastases, which means the cancer has spread to the brain, as long as these are not causing symptoms or are under control. The study will last for up to 36 months, during which patients will receive either dacomitinib or osimertinib first, followed by the other medication.

Participants will be randomly assigned to start with one of the two medications. The study will monitor how well the cancer responds to the treatment and how long the treatment remains effective. The goal is to find out which sequence of medications works best for patients with this type of lung cancer. This information could help doctors make better treatment decisions for future patients with similar conditions.

1 initial treatment phase

The trial begins with the administration of the first medication. Depending on the assigned group, the patient will receive either osimertinib or dacomitinib as the initial treatment.

Osimertinib is provided in the form of 80 mg film-coated tablets, taken orally once daily.

Dacomitinib is provided in the form of 15 mg film-coated tablets, taken orally once daily.

2 monitoring and assessment

Throughout the treatment, regular monitoring is conducted to assess the patient’s response to the medication. This includes imaging tests and other evaluations to measure the size and progression of the cancer.

The patient’s overall health and any side effects experienced are also monitored closely.

3 second-line treatment phase

If the initial treatment is no longer effective, the patient will switch to the second medication. If osimertinib was used first, the patient will switch to dacomitinib, and vice versa.

The dosage and administration remain the same: osimertinib as 80 mg tablets and dacomitinib as 15 mg tablets, both taken orally once daily.

4 ongoing evaluation

The patient’s response to the second-line treatment is evaluated similarly to the initial phase, with regular assessments and monitoring of health and side effects.

Adjustments to the treatment plan may be made based on these evaluations.

5 completion of trial

The trial is expected to conclude by July 31, 2025. At this point, a final assessment will be conducted to evaluate the overall effectiveness of the treatment sequence.

The results will contribute to understanding the best sequence of medications for treating advanced or metastatic non-small-cell lung cancer with EGFR mutations.

Who Can Join the Study?

Provide written informed consent to participate in the study.
Be a male or female patient aged 18 years or older.
Have a confirmed diagnosis of stage IIIB or IV NSCLC (a type of lung cancer) with specific changes in the EGFR gene, which can be detected through a tissue sample or blood test.
Be eligible to receive a specific treatment called osimertinib as the first or second treatment option, as decided by the doctor.
If you have brain metastases (cancer spread to the brain), they must be without symptoms and stable, meaning no worsening for at least two weeks before starting the study treatment.
Have no other genetic changes that drive cancer, such as KRAS, HER2, ALK, ROS1, MET, or BRAF mutations.
Have not received previous treatment with EGFR-TKI therapy (a type of cancer drug). Previous radiation or surgery for symptom relief is allowed, as well as certain chemotherapy if completed at least six months before the advanced cancer diagnosis.
Have at least one area of cancer that can be measured by imaging tests.
Have a performance status of 0-1, which means you are fully active or have some symptoms but can still carry out light work.
Be willing to follow the study procedures.
Have adequate bone marrow function, which means having enough blood cells to fight infection, prevent bleeding, and carry oxygen.
Have adequate liver function, meaning liver enzymes and bilirubin levels are within acceptable limits.
Have normal levels of alkaline phosphatase and creatinine, which are indicators of bone and kidney health.
Female patients must use effective birth control, not be breastfeeding, and have a negative pregnancy test before starting the study. Alternatively, they must be unable to have children due to menopause or surgery.
Male patients must agree to use condoms as a form of birth control.
Have no significant health issues that would prevent participation in the study, as determined by the doctor.

Who Cannot Join the Study?

Patients who have already received treatment for their advanced or metastatic EGFR mutation positive NSCLC cannot participate. This means if you have already been treated for this specific type of lung cancer, you are not eligible.
Patients with uncontrolled brain metastases are excluded. Brain metastases are cancer cells that have spread to the brain. If these are not under control, participation is not allowed.
Patients who are part of a vulnerable population are not eligible. This generally refers to groups who may need special protection or care, such as children or those unable to give consent.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Azienda Ospedaliero Universitaria Careggi	Florence	Italy
Ospedale Civile SS. Annunziata	Sassari	Italy

Other Sites

Site Name	City	Country
IRCCS Istituto Nazionale Tumori Fondazione Pascale	Naples	Italy
Azienda Ospedaliero Universitaria Di Modena	Modena	Italy
Azienda Ospedaliera Papardo	Messina	Italy
Ftybmvswsh Ilagz Pszfvoneiqi Stv Muywcw	Pavia	Italy
Ifnbnles Resoqpuom Pzx Lc Sanwyb Dga Tfeatd Dilr Aumejqb Ibbi Sxvhqz	Meldola	Italy
Urjxilebiuteejqdf Dbgve Ssfgc Do Vblfbe	Verona	Italy
Iijbn Oxcxsnes Ppcljngkkhc Sms Mwxjefp	Genoa	Italy
Akxfkaz Oggvikpssoojdzyxwcdrmtqpk Mizapgkz Dzcxq Calglc	Novara	Italy
Avcxjzl Oaddqribgec S Gbalxaun Afkkdtpjxl	Rome	Italy
Iftryqpl Tfevrj Bjqo Gjeqgeby Pfsuh Ih	Bari	Italy
Ajgvyje Strln Surgvdwvh Tujvnbiibxfn Ddu Sreek Ljohg	Varese	Italy
Izvldocr Owlowcxvoq Vbbman	Padua	Italy
Sbato Cvshsi Hzpjeymb Nmihzqjkl Djjzwomsnw	Trento	Italy
Igteu Ixkcwvlp Fizizbxnmkfyp Ovkdoqipgqws Iucdvfcr Ngnukwgdn tsvwhv Rjeaid Epygf	Rome	Italy
Owjjbxzz Sdr Ddqtih	Arezzo	Italy
Olhabdke “etntbvwd Mwbwltnx &jjitfy Tsedjb	Teramo	Italy
Ld Mukkfljzs Sdyfhc	Palermo	Italy
Cigsysyuce Sktzsbywr Pduv Tdawp	Sabadell	Spain
Ayqbuyj Svtgwtxel Lxxjzo Rrls 4	Civitavecchia	Italy
Hcisaksgf Caabjcm	Catania	Italy
Advqutq Und Tfsyfqz nhjy oyzdm	Leghorn	Italy
Iujxn Cqxu	Rionero In Vulture	Italy
Arsulos Uud Iptvi Dn Ryyrgd Etlfpy	Reggio Emilia	Italy
Aaqzkkn Uft Tihuydx Swa Eol	Arezzo	Italy
Auyulzz Urtgs Svkygumna Lssjjr Dm Pgdomnof	Piacenza	Italy
Ahoseta Ojbqfjpjejf S Mixjd Du Tlibg	Terni	Italy
Aaxnhfo Owkpojzgwwq Uobjzbnarryec Ppescczpgyr Pamrs Gfhdkexh	Palermo	Italy
Ogujlqcx Gtstmsfo Pnmfidfyolx Dl Mqqmqklp	Macerata	Italy
Hvjoldad Unafockwhgnwf Hmvusnao Twnup y Pvqjdz Iqcklomp Cllsbu dmfwjelscgbtwrtby (kkwd	Badalona	Spain
Akravle Sjnyw Szvesqebo Tvjjpcycxkjh Dhbsq Vkgog Otdgk	Saronno	Italy

Trial status

Country	Status	Recruitment Start
Italy	Not recruiting	16.06.2020
Spain	Not yet recruiting	16.06.2020

Trial locations

Investigated Drugs:

Dacomitinib is a medication used in this study to treat patients with advanced or metastatic non-small-cell lung cancer (NSCLC) that have specific mutations in the epidermal growth factor receptor (EGFR). It works by blocking the activity of the EGFR, which can help slow down or stop the growth of cancer cells. This study aims to understand how effective dacomitinib is, especially in patients who have brain metastases that are either asymptomatic or controlled.

Osimertinib is another medication being investigated in this study for its effectiveness in treating advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations. Like dacomitinib, osimertinib targets the EGFR to inhibit cancer cell growth. The study seeks to determine the best sequence of using these medications to achieve the most effective treatment outcomes for patients with these specific types of lung cancer.

Investigated Diseases:

Non-small cell lung cancer

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation – This is a type of lung cancer characterized by the presence of mutations in the epidermal growth factor receptor (EGFR) gene. These mutations lead to uncontrolled cell growth and division, contributing to the development and progression of cancer. NSCLC with EGFR mutations often presents as advanced or metastatic disease, meaning it has spread beyond the lungs to other parts of the body. The disease can include both classical and uncommon activating mutations, which influence how the cancer behaves and responds to treatment. Patients may experience symptoms such as persistent cough, chest pain, and difficulty breathing. The presence of brain metastases is possible, which can affect neurological function.

Trial ID:

2024-518223-29-00

Protocol code:

CAPLAND

NCT ID:

NCT04811001

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?